14 results on '"Beavers, Craig J."'
Search Results
2. Optimizing anticoagulation for patients receiving Impella support.
- Author
-
Beavers, Craig J., DiDomenico, Robert J., Dunn, Steven P., Cox, Jenna, To, Long, Weeks, Phillip, Trujillo, Toby C., and Jennings, Douglas L.
- Subjects
- *
HEPARIN , *ARTIFICIAL blood circulation , *ANTICOAGULANTS , *EXTRACORPOREAL membrane oxygenation - Abstract
Anticoagulation of patients treated with the Impella percutaneous mechanical circulatory support (MCS) devices is complex and lacks consistency across centers, potentially increasing the risk of complications. In order to optimize safety and efficacy, an expert committee synthesized all available evidence evaluating anticoagulation for patients receiving Impella support in order to provide consensus recommendations for the management of anticoagulation with these devices. The evidence synthesis led to the creation of 42 recommendations to improve anticoagulation management related to the use of the Impella devices. Recommendations address purge solution management, intravenous anticoagulation, monitoring, evaluation and management of heparin‐induced thrombocytopenia (HIT), and management during combination MCS support. The use of a heparinized, dextrose‐containing purge solution is critical for optimal device function, and a bicarbonate‐based purge solution may be an alternative in certain situations. Likewise, intravenous (ie, systemic) anticoagulation with heparin is often necessary, although evidence supporting the optimal assay and target range for monitoring the level of anticoagulation is generally lacking. Patients treated with an Impella MCS device may develop HIT, which is more difficult to evaluate and treat in this setting. Lastly, the use of Impella with extracorporeal membrane oxygenation or for biventricular support creates additional anticoagulation challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Use of Glycoprotein IIb/IIIa Inhibitors in the Modern Era of Acute Coronary Syndrome Management: A Survey of Cardiovascular Clinical Pharmacists.
- Author
-
Beavers, Craig J. and Jennings, Douglas L.
- Subjects
- *
ATTITUDES of medical personnel , *ACUTE coronary syndrome , *MYOCARDIAL infarction , *PHARMACISTS , *GLYCOPROTEINS , *QUESTIONNAIRES , *CHEMICAL inhibitors - Abstract
Evidence for the use of glycoprotein IIb/IIIa inhibitors (GPIs) in the management of acute coronary syndrome (ACS) is from the era of either limited utilization of P2Y12 inhibitors or prior the introduction of more potent P2Y12 inhibitors. This leads to divergent opinions regarding the role of these agents in contemporary practice. This study sought the opinion of cardiovascular clinical pharmacists regarding the role of GPIs in the modern of ACS management. A 13-question survey was created and distributed from June 2018 to July 2018 via the American College of Clinical Pharmacy's Cardiology Practice and Research Network e-mail listserv. The survey consisted of questions regarding the ideal use of GPIs in ACS management, preferred agent selection, and rational for selection. All results were analyzed with descriptive statistics. There were a total 69 responses of 1175 (response rate 5.9%). The majority felt there was still a role for GPI in accordance to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for ST-segment elevation myocardial infarction (65.2%), with eptifibatide being preferred (55.1%). For non-ST-segment myocardial infraction (NSTEMI), only 49.3% felt role of GPI was in line with the ACC/AHA guidelines, but a notable number of respondents felt GPIs were only indicated in NSTEMI patients for bailout or thrombotic complications (18.8%). A majority (56.5%) felt GPIs could be used as an alternative for cangrelor when bridging. The decision to use one agent over another were efficacy data, cost, and pharmacokinetic profile. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.
- Author
-
Cheng, Richard K., Kittleson, Michelle M., Beavers, Craig J., Birnie, David H., Blankstein, Ron, Bravo, Paco E., Gilotra, Nisha A., Judson, Marc A., Patton, Kristen K., and Rose-Bovino, Leonie
- Subjects
- *
SARCOIDOSIS , *MYOCARDITIS , *VENTRICULAR arrhythmia , *DIAGNOSIS , *SYMPTOMS , *CLINICAL trials - Abstract
Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion. Treatment should be initiated in individuals with clinical manifestations and active inflammation in a tiered approach, with corticosteroids as first-line treatment. The lack of randomized clinical trials in cardiac sarcoidosis has led to treatment decisions based on cohort studies and consensus opinions, with substantial variation observed across centers. This scientific statement is intended to guide clinical practice and to facilitate management conformity by providing a framework for the diagnosis and management of cardiac sarcoidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The National Practice Patterns of Venous Thromboembolism Prophylaxis Post-Cardiothoracic Surgery.
- Author
-
Mathew, Sheena E., Beavers, Craig J., and McNeely, Elizabeth
- Abstract
Background: The rates of venous thromboembolism (VTE) post-cardiothoracic surgery are not well understood. The american college of chest physicians (CHEST) guidelines report weak recommendations for starting VTE prophylaxis post-cardiothoracic surgery. It is suspected that due to the increase in bleed risk, postsurgery initiation of pharmacologic VTE prophylaxis is limited. Objective: The study sought to investigate the use of VTE prevention in US hospitals performing cardiac surgery and the use of mechanical/chemical prophylaxis postoperatively. Methods: This is a multicenter survey distributed to cardiac hospitals in the United States. The survey was distributed through 3 separate listservs. Data were analyzed utilizing descriptive statistics. Results: The majority of the hospitals were academic and/or community and completed coronary artery bypass graft (CABG), valve replacement (mitral/aortic/tricuspid), and aortic repair. It was common for hospitals to start mechanical and pharmacologic prophylaxis post-cardiothoracic surgery on postoperative day (POD) 1 to 2. The anticoagulation most commonly used consisted of unfractionated heparin. Conclusions: The majority of the institutions are initiating therapy POD 1 to 2 with both mechanical and chemical prophylaxis. The full impact of early initiation of VTE prophylaxis is unknown, and more studies are needed to assess the true risks/benefits of these practices. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Obesity and Antiplatelets-Does One Size Fit All?
- Author
-
Beavers, Craig J., Heron, Paula, Smyth, Susan S., Bain, Jonathan A., and Macaulay, Tracy E.
- Subjects
- *
PLATELET aggregation inhibitors , *OBESITY treatment , *VASCULAR diseases , *PHARMACODYNAMICS , *BODY mass index , *PATIENTS ,TREATMENT of vascular diseases - Abstract
Antiplatelet therapy has become a cornerstone in the management of many vascular diseases. With growing antiplatelet options, attention has focused on their comparative effectiveness in specific patient populations. Perhaps one of the least defined factors influencing efficacy of these agents is body mass and obesity. Evidence from preclinical models established that obesity promotes inflammation that in turn enhances platelet reactivity. Thus, adiposity has the potential to diminish or alter the therapeutic effect of antiplatelet therapy. Pharmacodynamic analyses suggest a potential need for dose adjustments of antiplatelet therapy in obese patients. Yet, obese patients paradoxically have better outcomes after acute coronary syndromes. In this review, we identify a critical need for clinical studies with outcome data to enable the development of recommendations for optimal antiplatelet regimens in obese individuals. Until such data exists, healthcare providers should be aware of the potential impact of obesity on the efficacy of anti-platelet therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. BICARBONATE-BASED PURGE SOLUTION DURING IMPELLA SUPPORT: A GROWING ALTERNATIVE.
- Author
-
Beavers, Craig J., Dunn, Steven P., DiDomenico, Robert J., Moretz, Jeremy, and Jennings, Douglas L.
- Published
- 2022
- Full Text
- View/download PDF
8. Distinguishing Anemia and Iron Deficiency of Heart Failure: Signal for Severity of Disease or Unmet Therapeutic Need?
- Author
-
Beavers, Craig J., Alburikan, Khalid A., Rodgers, Jo E., Dunn, Steven P., and Reed, Brent N.
- Subjects
- *
HEART failure , *IRON deficiency , *ANEMIA , *BLOOD transfusion , *INFLAMMATION - Abstract
Despite advances in the management of heart failure ( HF), quality of life and other outcomes remain suboptimal for many patients. Anemia and iron deficiency are comorbidities associated with adverse outcomes, although their pathophysiology in the setting of HF is not entirely understood. Anemia and iron deficiency may exist independently and may be a consequence of the systemic inflammatory state characterized by chronic HF. However, it is unclear whether serum hemoglobin concentrations and other hematologic parameters serve as markers for the severity of disease or represent novel therapeutic targets. Research in this area has focused primarily on therapies known to be effective for these conditions in other chronic disease states with similar pathophysiologic features (e.g., end-stage renal disease). Despite its many practical advantages, minimal evidence exists to support the use of oral iron supplementation in this setting. In contrast, intravenous iron has been the subject of several recent investigations, demonstrating improvements in both surrogate and clinical end points, although benefits seem to be the most substantial in patients with concomitant anemia. Erythropoietin-stimulating agents demonstrated early promise in retrospective analyses and small prospective trials, but their benefit was outweighed by a lack of improvement in clinical outcomes and an excess number of thromboembolic events in the largest trial of patients with anemia and HF to date. For acute symptomatic anemia, blood transfusion may be considered, although few trials have included patients with HF, and caution must be exerted in those who are hemodynamically unstable. Based on the currently available evidence, treatment of iron deficiency appears to confer benefit in patients with HF, whereas strategies aimed at improving hemoglobin alone do not. Included is a review of the pathophysiology of these conditions in the setting of HF, clinical trials evaluating pharmacologic therapy, and recommendations for management. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Meta-Analysis Comparing Carvedilol Versus Metoprolol for the Prevention of Postoperative Atrial Fibrillation Following Coronary Artery Bypass Grafting.
- Author
-
DiNicolantonio, James J., Beavers, Craig J., Menezes, Arthur R., Lavie, Carl J., O'Keefe, James H., Meier, Pascal, Vorobcsuk, András, Aradi, Dániel, Komócsi, András, Chatterjee, Saurav, D'Ascenzo, Fabrizio, Gasparini, Mauro, Brugts, Jasper, and Biondi-Zoccai, Giuseppe
- Subjects
- *
METOPROLOL , *ADRENERGIC beta blockers , *CORONARY artery bypass , *ATRIAL fibrillation prevention , *DISEASE incidence , *DRUG efficacy , *META-analysis ,PREVENTION of surgical complications - Abstract
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica (EMBASE) were searched up to March 2013 for suitable randomized controlled trials. Data were pooled using random-effects model for pairwise analyses. A total of 4 trials with 601 patients were included in this analysis. Pairwise analyses showed that compared with metoprolol, carvedilol significantly reduced the incidence of postoperative atrial fibrillation (odds ratio 0.50, 95% confidence interval 0.32 to 0.80). In conclusion, compared with metoprolol, carvedilol significantly reduces the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention: 2012 Update.
- Author
-
Dobesh, Paul P., Beavers, Craig J., Herring, Holly R., Spinler, Sarah A., Stacy, Zachary A., and Trujillo, Toby C.
- Subjects
- *
ACUTE coronary syndrome , *CARDIOVASCULAR disease treatment , *PATIENT management , *DRUG therapy , *PHARMACOGENOMICS , *CLOPIDOGREL , *CORONARY disease - Abstract
More than 1 million people in the United States experience an acute coronary syndrome ( ACS) every year, and almost 600,000 undergo percutaneous coronary intervention ( PCI) for treatment of cardiovascular disease. There is a large amount of evidence-based literature to guide appropriate management of these patients. There have been a number of advances in the treatment of these patients over the last several years. Due to the large amount of rapidly available literature concerning the care of patients with ACS or undergoing PCI, clinicians can often find it difficult to keep up with the information needed for optimizing care of these patients. Therefore, we provide the second update to the first compiled bibliography of key articles and guidelines relative to patients with ACS published in Pharmacotherapy in 2004. The initial update was published in Pharmacotherapy in 2007 and also included bibliographies concerning management of patients undergoing PCI. A number of guidelines and practice-changing literature have been published since the update in 2007. Specific areas included in this review are updated summaries of clinical practice guidelines and clinical trials of anticoagulants, antiplatelets, platelet aggregation testing, pharmacogenomics testing in patients taking clopidogrel, clopidogrel loading dose comparisons, clopidogrel and proton pump inhibitor drug interactions, the impact of bleeding in ACS, and statins. As with previous versions of this document, we hope that this compilation will serve as a resource for pharmacists, physicians, nurses, residents, and students responsible for the care of patients with coronary heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.
- Author
-
Kumbhani, Dharam J., Cannon, Christopher P., Beavers, Craig J., Bhatt, Deepak L., Cuker, Adam, Gluckman, Ty J., Marine, Joseph E., Mehran, Roxana, Messe, Steven R., Patel, Nimesh S., Peterson, Benjamin E., Rosenfield, Kenneth, Spinler, Sarah A., Thourani, Vinod H., and Writing Committee
- Subjects
- *
INTERNATIONAL normalized ratio , *PERCUTANEOUS coronary intervention , *CEREBRAL embolism & thrombosis , *ATRIAL fibrillation , *THROMBOEMBOLISM , *TRANSIENT ischemic attack , *LEGISLATIVE oversight , *CARDIOVASCULAR diseases , *CARDIOVASCULAR disease treatment , *ATRIAL fibrillation treatment , *CARDIOLOGY , *VEINS , *MEDICAL care , *CARDIOVASCULAR system , *PLATELET aggregation inhibitors , *MEDICAL societies , *DISEASE complications ,THROMBOEMBOLISM prevention - Abstract
This article has been temporarily removed as it was inadvertently posted ahead of an agreed-upon embargo. The article will be reinstated upon embargo expiry. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Effective medications can work only in patients who take them: Implications for post‐acute heart failure care.
- Author
-
Cotter, Gad, Davison, Beth A., Adams, Kirkwood F., Ambrosy, Andrew P., Atabaeva, Lina, Beavers, Craig J., Bhatt, Ankeet S., Givertz, Michael M., Grodin, Justin L., Lala, Anuradha, Novosadov, Mikhail, Sokos, George G., Takagi, Koji, Teerlink, John R., and Bhatt, Deepak L.
- Subjects
- *
HEART failure , *PATIENTS' attitudes , *DRUGS , *MEDICAL personnel , *PATIENT compliance , *QUALITY of life , *CLINICAL trials monitoring - Abstract
Acute heart failure (AHF) is a common cause of hospitalization, particularly among older individuals, and has high mortality and readmission rates. Adherence to guideline-directed medical therapy (GDMT) is crucial for improving outcomes in heart failure (HF) patients, as non-adherence can lead to exacerbations and adverse outcomes. However, studies have shown that medication non-adherence rates among HF patients can be as high as 70%. Various factors contribute to non-adherence, including patient circumstances, treatment-related factors, and healthcare system and payer factors. Adherence interventions, such as patient education, medication regimen management, and reminders, have been shown to improve medication adherence and reduce mortality and hospital readmissions in HF patients. Improving adherence to GDMT is essential for improving AHF outcomes, and further research is needed to identify effective approaches to enhance medication adherence. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
13. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
- Author
-
Noel, Zachary R. and Beavers, Craig J.
- Subjects
- *
PROPROTEIN convertases , *SUBTILISINS , *ENZYME inhibitors , *LOW density lipoproteins , *DRUG interactions - Abstract
Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. The role of the clinical pharmacist in the care of patients with cardiovascular disease.
- Author
-
Dunn, Steven P., Birtcher, Kim K., Beavers, Craig J., Baker, William L., Brouse, Sara D., IIPage, Robert L., Bittner, Vera, Walsh, Mary Norine, and Page, Robert L 2nd
- Abstract
Team-based cardiovascular care, including the use of clinical pharmacists, can efficiently deliver high-quality care. This Joint Council Perspectives paper from the Cardiovascular Team and Prevention Councils of the American College of Cardiology provides background information on the clinical pharmacist's role, training, certification, and potential utilization in a variety of practice models. Selected systematic reviews and meta-analyses, highlighting the benefit of clinical pharmacy services, are summarized. Clinical pharmacists have a substantial effect in a wide variety of roles in inpatient and ambulatory settings, largely through optimization of drug use, avoidance of adverse drug events, and transitional care activities focusing on medication reconciliation and patient education. Expansion of clinical pharmacy services is often impeded by policy, legislation, and compensation barriers. Multidisciplinary organizations, including the American College of Cardiology, should support efforts to overcome these barriers, allowing pharmacists to deliver high-quality patient care to the full extent of their education and training. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.